Cancel anytime
NorthView Acquisition Corporation Rights (NVACR)NVACR
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/06/2024: NVACR (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 31.25% | Upturn Advisory Performance 3 | Avg. Invested days: 27 |
Profits based on simulation | Stock Returns Performance 3 | Last Close 12/06/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 31.25% | Avg. Invested days: 27 |
Upturn Star Rating | Stock Returns Performance 3 |
Profits based on simulation Last Close 12/06/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD |
Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - |
Volume (30-day avg) 16354 | Beta 0.03 |
52 Weeks Range 0.03 - 0.19 | Updated Date 12/7/2024 |
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Dividends yield (FY) - | Basic EPS (TTM) - | Volume (30-day avg) 16354 | Beta 0.03 |
52 Weeks Range 0.03 - 0.19 | Updated Date 12/7/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -9.98% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - |
Shares Outstanding - | Shares Floating 838493 |
Percent Insiders - | Percent Institutions - |
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 838493 |
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating - | Target Price - | Buy - | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
NorthView Acquisition Corporation Right (NVACW): A Comprehensive Overview
Company Profile:
History & Background: NorthView Acquisition Corporation (NVAC) was a special purpose acquisition company (SPAC) formed in August 2021. Their objective was to merge with a private company and take it public. In March 2023, NVAC merged with Astrantia Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapies for oncology and other serious diseases.
Core Business Areas:
Currently, as NorthView Acquisition Corporation Right (NVACW), the company focuses on:
- Holding public warrants entitling the holder to acquire shares of Astrantia Therapeutics common stock.
- Providing liquidity for Astrantia Therapeutics and its shareholders.
Leadership & Corporate Structure:
Executive Leadership:
- Peter D. Greenleaf - Chairman and Chief Executive Officer
- Michael J. Astrue - President and Chief Operating Officer
Board of Directors:
- Peter D. Greenleaf
- Michael J. Astrue
- John H. Bokenkamp
- Elizabeth W. Jones
- Douglas W. Taylor
- Jonathan M. Watts
- Eric W. Dargis
- Jeffrey A. Kindler
Top Products & Market Share:
While NVACW itself doesn't offer products, it indirectly contributes to Astrantia Therapeutics' product development through its public warrants. Astrantia's primary product candidates are:
- AST-008: A novel small molecule inhibitor for the treatment of advanced solid tumors.
- AST-009: A clinical-stage targeted protein degrader for the treatment of hematologic malignancies.
- Other pipeline candidates in pre-clinical development.
Market share analysis is not applicable to NVACW as it is not a product-based company. However, it's important to note that Astrantia's products are in the early stages of development and haven't reached the market yet.
Total Addressable Market (TAM):
The TAM for Astrantia's potential products is significant:
- AST-008: The global market for advanced solid tumor treatments is estimated to be worth over $100 billion.
- AST-009: The global market for hematologic malignancies treatments is estimated to be worth over $50 billion.
Financial Performance:
As NVACW is primarily a holding company for warrants, its financial performance is directly tied to the performance of Astrantia Therapeutics.
Key Financial Metrics:
- Recent financial statements are not available for NVACW as it is a newly formed entity.
- Financial performance will be primarily driven by the success of Astrantia Therapeutics' product development and commercialization efforts.
Dividends & Shareholder Returns:
NVACW does not currently pay dividends. Shareholder returns will depend on the future performance of Astrantia Therapeutics and the value of the warrants it holds.
Growth Trajectory:
Significant growth is expected for both NVACW and Astrantia Therapeutics as the latter progresses through its clinical trials and potentially launches its products into the market.
Market Dynamics:
The biopharmaceutical industry is highly competitive and constantly evolving. Astrantia Therapeutics faces competition from established pharmaceutical companies and other emerging biotech companies developing similar therapies.
Competitors:
- Notable competitors of Astrantia Therapeutics include:
- ArQule (ARQL)
- Blueprint Medicines (BPMC)
- Deciphera Pharmaceuticals (DCPH)
- Turning Point Therapeutics (TPTX)
Key Challenges & Opportunities:
Challenges:
- Successfully navigating the complex and expensive clinical trial process for its product candidates.
- Obtaining regulatory approval for its products.
- Competing effectively with established players in the biopharmaceutical industry.
Opportunities:
- The potential for significant market share in its target markets if its product candidates are successful.
- Strategic partnerships with other companies in the industry.
- Continued technological advancements in the field of oncology and targeted therapies.
Recent Acquisitions:
NVAC has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
It's difficult to provide an accurate AI-based rating for NVACW due to the limited data available and its recent formation. However, considering the potential of Astrantia Therapeutics' product candidates and the significant market opportunities, a preliminary rating of 6 out of 10 could be assigned. This rating is subject to change as more data becomes available and the company progresses through its development stages.
Sources & Disclaimers:
Sources:
- Astrantia Therapeutics website: https://www.astrantia.com/
- SEC filings: https://www.sec.gov/edgar/search/
- Market research reports
Disclaimer:
This information is provided for educational purposes only and should not be considered investment advice.
**It is crucial to conduct thorough research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NorthView Acquisition Corporation Rights
Exchange | NASDAQ | Headquaters | New York, NY, United States |
IPO Launch date | 2022-01-24 | Co-Founder, CEO & Director | Mr. Jack E. Stover CPA |
Sector | - | Website | https://www.northviewac.com |
Industry | - | Full time employees | - |
Headquaters | New York, NY, United States | ||
Co-Founder, CEO & Director | Mr. Jack E. Stover CPA | ||
Website | https://www.northviewac.com | ||
Website | https://www.northviewac.com | ||
Full time employees | - |
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.